title: Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
abstract: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has demonstrated clinical benefit in metastatic breast cancer (MBC) in a randomized phase III trial versus paclitaxel (CA012; N = 454) and in a randomized phase II trial versus docetaxel (CA024; N = 300). This retrospective analysis examines whether patients with poor prognostic factors demonstrate similar outcomes to the intent-to-treat (ITT) populations in these trials. This retrospective analysis evaluated the efficacy and safety of previously untreated patients with MBC with the following poor prognostic factors: visceral dominant metastases and short disease-free interval (DFI; ≤2 years). In CA012 (n = 186 first-line patients), nab-paclitaxel demonstrated a significantly higher overall response rate (ORR) versus paclitaxel in patients with visceral dominant metastases (42 vs. 23 %; P = 0.022), whereas the higher ORR for nab-paclitaxel in patients with a short DFI (43 vs. 33 %; P = NS) was not statistically significant. In CA024, a significantly higher ORR for nab-paclitaxel 150 mg/m(2) versus docetaxel was observed in patients with visceral dominant metastases (76 vs. 37 %; P < 0.001). No significant differences in ORR were observed in patients with a short DFI. Although progression-free survival (PFS) and overall survival showed trends similar to ORR, statistical significance was only achieved for comparisons of PFS in patients with visceral dominant metastases in CA024 (13.1 months for nab-paclitaxel 150 mg/m(2) vs. 7.8 months for docetaxel [P = 0.019] and 7.5 months for nab-paclitaxel 100 mg/m(2) [P = 0.010]). Safety results were similar to previous reports of the ITT populations. nab-Paclitaxel demonstrated similar efficacy in patients with poor prognostic factors as in the ITT populations of these two trials. In each trial, ORR was significantly higher for nab-paclitaxel versus the comparator taxane among patients with visceral dominant metastases.
authors.affiliation: Baylor Sammons Cancer Center, Texas Oncology and The US Oncology Network, 3410 Worth Street, Ste 400, Dallas, TX 75246, USA. Joyce.oshaughnessy@usoncology.com
authors.forename: Joyce
authors.initials: J
authors.lastname: O'Shaughnessy
authors.forename: William J
authors.initials: WJ
authors.lastname: Gradishar
authors.forename: Paul
authors.initials: P
authors.lastname: Bhar
authors.forename: Jose
authors.initials: J
authors.lastname: Iglesias
mesh_terms: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000009:adverse effects / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D053758:Nanoparticles; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel
references.citation: Breast Cancer Res Treat. 1999 Jul;56(1):67-78
references.pmid: 10517344
references.citation: Clin Breast Cancer. 2012 Oct;12(5):313-21
references.pmid: 22728026
references.citation: J Clin Oncol. 1995 Oct;13(10):2575-81
references.pmid: 7595709
references.citation: Eur J Cancer. 1996 Jan;32A(1):47-51
references.pmid: 8695240
references.citation: Eur J Surg Oncol. 2007 May;33(4):420-3
references.pmid: 17049430
references.citation: Breast Cancer Res Treat. 2006 Mar;96(1):53-62
references.pmid: 16319993
references.citation: Breast Cancer Res Treat. 1992;21(3):173-80
references.pmid: 1515652
references.citation: J Clin Oncol. 1996 Jun;14(6):1858-67
references.pmid: 8656254
references.citation: Oncologist. 2005;10 Suppl 3:20-9
references.pmid: 16368868
references.citation: Breast. 2011 Oct;20(5):468-74
references.pmid: 21843943
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3611-9
references.pmid: 19470941
references.citation: Breast Cancer Res Treat. 2001 Mar;66(1):33-9
references.pmid: 11368408
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7794-803
references.pmid: 16172456
references.citation: J Clin Oncol. 2012 May 10;30(14):1705-11
references.pmid: 22430273
references.citation: Clin Pharmacokinet. 2003;42(7):665-85
references.pmid: 12844327
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437